Which CRC Regimens Are More Likely to Harm Kidneys?

After analyzing various treatments for metastatic colorectal cancer (CRC), researchers zeroed in on FOLFIRI + bevacizumab. The study was published as a preprint and has not yet been peer reviewed.
First Look

source https://www.medscape.com/viewarticle/974095?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?